To include your compound in the COVID-19 Resource Center, submit it here.

Biogen reports Amevive Phase II data

BGEN said that in an on-going Phase II retreatment trial in 174

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE